• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

痰液颜色:非囊性纤维化支气管扩张症中的一种有用临床工具。

Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis.

作者信息

Murray M P, Pentland J L, Turnbull K, MacQuarrie S, Hill A T

机构信息

Department of Respiratory Medicine, Royal Infirmary, University of Edinburgh, Edinburgh, UK.

出版信息

Eur Respir J. 2009 Aug;34(2):361-4. doi: 10.1183/09031936.00163208.

DOI:10.1183/09031936.00163208
PMID:19648517
Abstract

This study explored the utility of sputum colour in clinically stable patients with bronchiectasis. Interpretation of sputum colour between the doctor and the patient was reliable (intraclass correlation coefficient 0.83 (95% confidence interval 0.76-0.89). Sputum colour predicted bacterial colonisation (5% in mucoid sputum; 43.5% in mucopurulent sputum; 86.4% in purulent sputum; p<0.0001). On multivariate logistic regression analysis, independent factors associated with purulent sputum were bacterial colonisation, varicose or cystic bronchiectasis, forced expiratory volume in 1 s <80% predicted and diagnosis of bronchiectasis aged <45 yrs.

摘要

本研究探讨了痰液颜色在临床稳定的支气管扩张症患者中的应用价值。医生与患者之间对痰液颜色的判断具有可靠性(组内相关系数为0.83(95%置信区间为0.76 - 0.89))。痰液颜色可预测细菌定植情况(黏液性痰液中为5%;黏液脓性痰液中为43.5%;脓性痰液中为86.4%;p<0.0001)。多因素逻辑回归分析显示,与脓性痰液相关的独立因素包括细菌定植、静脉曲张型或囊状支气管扩张、1秒用力呼气容积<预测值的80%以及45岁以下诊断为支气管扩张症。

相似文献

1
Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis.痰液颜色:非囊性纤维化支气管扩张症中的一种有用临床工具。
Eur Respir J. 2009 Aug;34(2):361-4. doi: 10.1183/09031936.00163208.
2
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).目的痰色评估与支气管扩张症的临床结局:来自欧洲支气管扩张症注册研究(EMBARC)的数据。
Eur Respir J. 2024 Apr 18;63(4). doi: 10.1183/13993003.01554-2023. Print 2024 Apr.
3
Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis.261例有症状支气管扩张症患者CT表现与临床评估的相关性
AJR Am J Roentgenol. 1999 Jul;173(1):53-8. doi: 10.2214/ajr.173.1.10397099.
4
Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.痰液细菌学对支气管扩张症患者生活质量的影响。
Eur Respir J. 1997 Aug;10(8):1754-60. doi: 10.1183/09031936.97.10081754.
5
Prevalence and factors associated with isolation of Aspergillus and Candida from sputum in patients with non-cystic fibrosis bronchiectasis.非囊性纤维化支气管扩张症患者痰液中分离出曲霉菌和念珠菌的患病率及相关因素
Respiration. 2015;89(5):396-403. doi: 10.1159/000381289. Epub 2015 Apr 23.
6
The response of patients with purulent bronchiectasis to antibiotics for four months.化脓性支气管扩张症患者使用抗生素四个月的反应。
Q J Med. 1988 Feb;66(250):163-73.
7
A novel microbiota stratification system predicts future exacerbations in bronchiectasis.一种新的微生物组分层系统可预测支气管扩张症的未来恶化。
Ann Am Thorac Soc. 2014 May;11(4):496-503. doi: 10.1513/AnnalsATS.201310-335OC.
8
Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.支气管扩张症患者的细菌定植:微生物学模式及危险因素
Thorax. 2002 Jan;57(1):15-9. doi: 10.1136/thorax.57.1.15.
9
Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease.痰的颜色是慢性阻塞性肺疾病细菌定植的标志物。
Respir Res. 2010 May 14;11(1):58. doi: 10.1186/1465-9921-11-58.
10
A pilot study of low-dose erythromycin in bronchiectasis.低剂量红霉素治疗支气管扩张症的一项初步研究。
Eur Respir J. 1999 Feb;13(2):361-4. doi: 10.1183/09031936.99.13236199.

引用本文的文献

1
Neutrophilic inflammation in bronchiectasis.支气管扩张症中的中性粒细胞性炎症。
Eur Respir Rev. 2025 Apr 2;34(176). doi: 10.1183/16000617.0179-2024. Print 2025 Apr.
2
The impact of Tanreqing injection on mucus hypersecretion and cough in bronchiectasis: A meta-analysis of randomized controlled trials.痰热清注射液对支气管扩张症黏液高分泌和咳嗽的影响:一项随机对照试验的荟萃分析。
Medicine (Baltimore). 2024 Nov 8;103(45):e40465. doi: 10.1097/MD.0000000000040465.
3
Disease Severity and Activity in Bronchiectasis: A Paradigm Shift in Bronchiectasis Management.
支气管扩张症的疾病严重程度与活动度:支气管扩张症管理的范式转变
Tuberc Respir Dis (Seoul). 2025 Jan;88(1):109-119. doi: 10.4046/trd.2024.0120. Epub 2024 Aug 30.
4
Total sputum nitrate/nitrite is associated with exacerbations and colonisation in bronchiectasis.痰液中总硝酸盐/亚硝酸盐水平与支气管扩张症的病情加重及细菌定植有关。
ERJ Open Res. 2024 Jul 22;10(4). doi: 10.1183/23120541.01045-2023. eCollection 2024 Jul.
5
Biomarkers in bronchiectasis.支气管扩张症的生物标志物。
Eur Respir Rev. 2024 Jul 3;33(173). doi: 10.1183/16000617.0234-2023. Print 2024 Jul.
6
Correlating Reiff scores with clinical, functional, and prognostic factors: characterizing noncystic fibrosis bronchiectasis severity: validation from a nationwide multicenter study in Taiwan.将 Reiff 评分与临床、功能和预后因素相关联:描述非囊性纤维化支气管扩张症的严重程度:来自台湾全国多中心研究的验证。
Eur J Med Res. 2024 May 14;29(1):286. doi: 10.1186/s40001-024-01870-z.
7
[Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Consensus for post-COVID-19 Clinical Follow-up].[西班牙肺科与胸外科协会(SEPAR)关于新冠后临床随访的共识]
Open Respir Arch. 2020 Oct-Dec;2(4):278-283. doi: 10.1016/j.opresp.2020.09.002. Epub 2020 Oct 13.
8
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).目的痰色评估与支气管扩张症的临床结局:来自欧洲支气管扩张症注册研究(EMBARC)的数据。
Eur Respir J. 2024 Apr 18;63(4). doi: 10.1183/13993003.01554-2023. Print 2024 Apr.
9
Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty.吸入用氨溴索在伴有黏液脓性痰及咳痰困难的住院成年患者中的安全性和有效性评估。
Front Med (Lausanne). 2023 May 25;10:1182602. doi: 10.3389/fmed.2023.1182602. eCollection 2023.
10
Sputum handling for rheology.痰液处理流变学。
Sci Rep. 2023 May 11;13(1):7695. doi: 10.1038/s41598-023-34043-9.